Investor Presentaiton
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations
THE
Disease Area
Diabetes
Inflammation
Immuno-
oncology
Touching a billion
lives through
affordable innovation
Asset
Insulin Tregopil- a first-in-class oral, prandial
Insulin
Itolizumab- A novel humanized CD6
antibody
$
Biocon
Current Progress
Phase I multiple ascending dose studies in Type 1 DM patients making good
progress in Germany. This trial is in partnership with the US-based Juvenile Diabetes
Research Foundation (JDRF), a leading non-profit organisation.
•
Phase 1 component of this trial expected to be completed in FY22
•
US, Canada, Australia and New Zealand rights out-licensed to the US-based
Equilluim Inc. Currently, Equillium is conducting clinical trials on the use of
Itolizumab in the treatment of acute graft-versus-host disease (aGVHD),
uncontrolled asthma and lupus nephritis.
In 2020, Itolizumab was repurposed for the prevention and treatment of COVID-19
complications and we were granted Restricted Emergency Use approval in
September 2020 for the treatment of Cytokine Release Syndrome (CRS) in
moderate to Severe Acute Respiratory Distress Syndrome (ARDS) patients in India.
Additional data is being collected as part of Phase 4 (post-marketing study) and
Real-World Evidence (RWE) from COVID-19 patients.
BCA101- (formerly FmAb2, a first-in-class
EGFR / TGFß-trap bifunctional antibody). This
asset is part of Bicara Therapeutics, a
wholly owned subsidiary of Biocon and a
clinical-stage biotechnology company based
in US
.
Entered a Phase 1/2 study at leading US and Canadian cancer centers in July
2020.
Under evaluation, both as a single agent and in combination with the checkpoint
inhibitor Pembrolizumab, in patients with advanced EGFR-driven solid tumors, who
no longer respond to the standard of care.
Bicara anticipates transitioning to dose expansion studies in the second half of
2021.
11View entire presentation